These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31723796)

  • 1. A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML.
    Schwarer AP; Butler J; Jackson K; Beligaswatte A; Martin L; Kennedy G; Daniela Z; Lewis I; Hiwase D; Wight J; He S; Grigg A; Morris K; Mollee P; Marlton P
    Hemasphere; 2018 Dec; 2(6):e158. PubMed ID: 31723796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
    Miyamoto T; Nagafuji K; Fujisaki T; Uchida N; Matsue K; Henzan H; Ogawa R; Takase K; Aoki T; Hidaka M; Teshima T; Taniguchi S; Akashi K; Harada M;
    Int J Hematol; 2018 Apr; 107(4):468-477. PubMed ID: 29243031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
    Hanoun M; Ruhnke L; Kramer M; Hanoun C; Schäfer-Eckart K; Steffen B; Sauer T; Krause SW; Schliemann C; Mikesch JH; Kaufmann M; Hänel M; Jost E; Brümmendorf TH; Fransecky L; Kraus S; Einsele H; Niemann D; Neubauer A; Kullmer J; Seggewiss-Bernhard R; Görner M; Held G; Kaiser U; Scholl S; Hochhaus A; Reinhardt HC; Platzbecker U; Baldus CD; Müller-Tidow C; Bornhäuser M; Serve H; Röllig C;
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4611-4621. PubMed ID: 36167894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry.
    Chanswangphuwana C; Polprasert C; Owattanapanich W; Kungwankiattichai S; Rattarittamrong E; Rattanathammethee T; Limvorapitak W; Saengboon S; Niparuck P; Puavilai T; Julamanee J; Saelue P; Wanitpongpun C; Nakhakes C; Prayongratana K; Sriswasdi C
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e915-e921. PubMed ID: 35792033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
    Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
    Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
    Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
    Tangchitpianvit K; Rattarittamrong E; Chai-Adisaksopha C; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Tantiworawit A; Norasetthada L
    Hematology; 2021 Dec; 26(1):355-364. PubMed ID: 33853503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.
    Zhou JH; Lin HQ; Shen Q; Hu LN; Li GQ; Sun XF; Zhang XY
    Curr Med Sci; 2018 Feb; 38(1):51-57. PubMed ID: 30074151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients.
    Ciftciler R; Demiroglu H; Buyukasık Y; Okay M; Aksu S; Sayınalp N; Malkan UY; Haznedaroglu IC; Ozcebe O; Goker H
    Transfus Apher Sci; 2018 Dec; 57(6):752-755. PubMed ID: 30249531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study.
    Chen G; Yang J; Cao F; Zhou W; Gong D; Liu L; Zhou D
    Ann Transl Med; 2022 Aug; 10(16):858. PubMed ID: 36111020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
    Zhang W; Ding Y; Wu H; Chen Y; Lu H; Chen C; Fu J; Wang W; Liang A; Zou S
    Medicine (Baltimore); 2014 Dec; 93(27):e134. PubMed ID: 25501050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
    Lowenthal RM; Bradstock KF; Matthews JP; Bishop JF; Juneja S; Cobcroft R; Eliadis P; Enno A; Gill D; Herrmann RP; Manoharan A; Page FJ; Rooney KF; Rosenfeld D; Seldon M; Taylor KM; Wolf MM; Young GA
    Leuk Lymphoma; 1999 Aug; 34(5-6):501-10. PubMed ID: 10492073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
    Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A
    Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.
    Karanes C; Kopecky KJ; Head DR; Grever MR; Hynes HE; Kraut EH; Vial RH; Lichtin A; Nand S; Samlowski WE; Appelbaum FR
    Leuk Res; 1999 Sep; 23(9):787-94. PubMed ID: 10475617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
    Jourdan E; Rigal-Huguet F; Marit G; Vey N; Dastugue N; Fegueux N; Molina L; Gastaut JA; Legros L; Zerazhi H; Cailleres S; Bauduer F; Bordessoule D; Attal M; Blaise D; Pigneux A;
    Br J Haematol; 2005 May; 129(3):403-10. PubMed ID: 15842665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
    Capizzi RL; Davis R; Powell B; Cuttner J; Ellison RR; Cooper MR; Dillman R; Major WB; Dupre E; McIntyre OR
    J Clin Oncol; 1988 Mar; 6(3):499-508. PubMed ID: 3162515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK).
    Fopp M; Fey MF; Bacchi M; Cavalli F; Gmuer J; Jacky E; Schmid L; Tichelli A; Tobler A; Tschopp L; Von Fliedner V; Gratwohl A
    Ann Oncol; 1997 Mar; 8(3):251-7. PubMed ID: 9137794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of HIDAC 18 g Versus IDAC 9 g in Consolidation Therapy of Acute Myeloid Leukemia: A Retrospective Study.
    Ravikumar D; Saju H; Choudary A; Bhattacharjee A; Dubashi B; Ganesan P; Kayal S
    Indian J Hematol Blood Transfus; 2022 Jan; 38(1):31-41. PubMed ID: 35125710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
    Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
    Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission.
    Vydra J; Šálek C; Schwarz J; Žák P; Novák J; Petečuková V; Pecherková P; Mayer J; Cetkovský P; Ráčil Z
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):106-113. PubMed ID: 29289481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.